Brian A. Droz
Eli Lilly (United States)(US)
Publications by Year
Research Areas
Adipose Tissue and Metabolism, Regulation of Appetite and Obesity, Neuropeptides and Animal Physiology, Diabetes Treatment and Management, Pancreatic function and diabetes
Most-Cited Works
- → GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice(2021)209 cited
- → Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist(2020)176 cited
- → Validation of Diacyl Glycerolacyltransferase I as a Novel Target for the Treatment of Obesity and Dyslipidemia Using a Potent and Selective Small Molecule Inhibitor(2008)139 cited
- → Tirzepatide induces a thermogenic-like amino acid signature in brown adipose tissue(2022)79 cited
- → Discovery and Metabolic Stabilization of Potent and Selective 2-Amino-N-(adamant-2-yl) Acetamide 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitors(2006)77 cited
- → GIPR Agonism Inhibits PYY-Induced Nausea-Like Behavior(2022)61 cited
- → Discovery and Pharmacological Evaluation of Growth Hormone Secretagogue Receptor Antagonists(2006)50 cited
- → Optimization of Chromone-2-carboxamide Melanin Concentrating Hormone Receptor 1 Antagonists: Assessment of Potency, Efficacy, and Cardiovascular Safety(2006)48 cited
- → 2,4-Diaminopyrimidine Derivatives as Potent Growth Hormone Secretagogue Receptor Antagonists(2006)45 cited
- → The GIP receptor activates futile calcium cycling in white adipose tissue to increase energy expenditure and drive weight loss in mice(2024)41 cited